[
  {
    "ts": null,
    "headline": "Jury: Johnson & Johnson Liabile in Case Linking Baby Powder to Cancer",
    "summary": "On Friday, a Pennsylvania state-court jury in Philadelphia ordered Johnson & Johnson (NYSE:JNJ) to pay $250,000 to the family of Gayle Emerson, finding the company liable in a case blaming its talc baby powder for her ovarian cancer. The verdict lands as the company also fights over whether jurors will hear scientific experts in the consolidated federal docket, including a New Jersey special master's recommendation that would let plaintiffs present causation testimony, a fight detailed in key ex",
    "url": "https://finnhub.io/api/news?id=bfd89e02e37e4ba83ec28ebd92b976d0811b078b529ae4199a8cfda4137110ea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771363819,
      "headline": "Jury: Johnson & Johnson Liabile in Case Linking Baby Powder to Cancer",
      "id": 139126555,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "On Friday, a Pennsylvania state-court jury in Philadelphia ordered Johnson & Johnson (NYSE:JNJ) to pay $250,000 to the family of Gayle Emerson, finding the company liable in a case blaming its talc baby powder for her ovarian cancer. The verdict lands as the company also fights over whether jurors will hear scientific experts in the consolidated federal docket, including a New Jersey special master's recommendation that would let plaintiffs present causation testimony, a fight detailed in key ex",
      "url": "https://finnhub.io/api/news?id=bfd89e02e37e4ba83ec28ebd92b976d0811b078b529ae4199a8cfda4137110ea"
    }
  },
  {
    "ts": null,
    "headline": "Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment",
    "summary": "William Blair upgrades Neumora after strong Alzheimer&#39;s agitation data, sees upside from NMRA-511 and obesity pipeline potential.",
    "url": "https://finnhub.io/api/news?id=682ec5fcbc0b6d53ef40562c78693447bab30c5bff0f68f490ce3ec87b9347dc",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771342340,
      "headline": "Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment",
      "id": 139134440,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/17/Beyond-Alzheimers-Treatments.jpeg?width=2048&height=1536",
      "related": "JNJ",
      "source": "Benzinga",
      "summary": "William Blair upgrades Neumora after strong Alzheimer&#39;s agitation data, sees upside from NMRA-511 and obesity pipeline potential.",
      "url": "https://finnhub.io/api/news?id=682ec5fcbc0b6d53ef40562c78693447bab30c5bff0f68f490ce3ec87b9347dc"
    }
  },
  {
    "ts": null,
    "headline": "Beat the Market the Zacks Way: Micron Technology, Cooper Companies, Coeur Mining in Focus",
    "summary": "Micron Technology surges 66.8% in 12 weeks as Zacks spotlights standout picks beating a volatile market despite tech selloff.",
    "url": "https://finnhub.io/api/news?id=9136cb2fad27c2927ba65b943fd07b1d0b70c06e4af002dd96afc7c8a80dc045",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771338420,
      "headline": "Beat the Market the Zacks Way: Micron Technology, Cooper Companies, Coeur Mining in Focus",
      "id": 139123946,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Micron Technology surges 66.8% in 12 weeks as Zacks spotlights standout picks beating a volatile market despite tech selloff.",
      "url": "https://finnhub.io/api/news?id=9136cb2fad27c2927ba65b943fd07b1d0b70c06e4af002dd96afc7c8a80dc045"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Down Since Q4 Earnings Report: How to Play the Stock",
    "summary": "ABBV stock declines since it announced earnings results on Feb. 4. Skyrizi and Rinvoq fuel growth, offsetting Humira erosion.",
    "url": "https://finnhub.io/api/news?id=92bd175d0f32a0e0fb04227bca20e9dc19a05be6e178f06dcce127e222d25874",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771336620,
      "headline": "AbbVie Down Since Q4 Earnings Report: How to Play the Stock",
      "id": 139123920,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "ABBV stock declines since it announced earnings results on Feb. 4. Skyrizi and Rinvoq fuel growth, offsetting Humira erosion.",
      "url": "https://finnhub.io/api/news?id=92bd175d0f32a0e0fb04227bca20e9dc19a05be6e178f06dcce127e222d25874"
    }
  },
  {
    "ts": null,
    "headline": "Behind the Scenes of Johnson & Johnson's Latest Options Trends",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=8077905c6d0164aa4bc38fbdadfa91b9580133a57a66fd1561f4139ebf4c5e87",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771333253,
      "headline": "Behind the Scenes of Johnson & Johnson's Latest Options Trends",
      "id": 139135053,
      "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/movers_3.jpg?width=2048&height=1536",
      "related": "JNJ",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=8077905c6d0164aa4bc38fbdadfa91b9580133a57a66fd1561f4139ebf4c5e87"
    }
  },
  {
    "ts": null,
    "headline": "FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced the U.S. Food and Drug Administration (FDA) has approved a new, simplified monthly dosing schedule* for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj). When administered in combination with oral LAZCLUZE® (lazertinib) for the first-line treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC), monthly dosing delivers consistent outcomes with the previously approved bi-weekly subcutaneous (SC) do",
    "url": "https://finnhub.io/api/news?id=04a477cbf2abe8877f806bb099b420848cfd5bb1c702cf71014bfbf6668b374a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771333200,
      "headline": "FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month",
      "id": 139122101,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced the U.S. Food and Drug Administration (FDA) has approved a new, simplified monthly dosing schedule* for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj). When administered in combination with oral LAZCLUZE® (lazertinib) for the first-line treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC), monthly dosing delivers consistent outcomes with the previously approved bi-weekly subcutaneous (SC) do",
      "url": "https://finnhub.io/api/news?id=04a477cbf2abe8877f806bb099b420848cfd5bb1c702cf71014bfbf6668b374a"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson's New FDA Approval Lets Lung Cancer Patients Switch To Monthly Dosing Sooner",
    "summary": "FDA approves monthly dosing for J&amp;J&#39;s Rybrevant Faspro with Lazcluze, offering faster, easier treatment for EGFR lung cancer.",
    "url": "https://finnhub.io/api/news?id=cc3da2c18854fedc1a4497c91ee139328afde52de59950129cfba66b5d2ea082",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771332355,
      "headline": "Johnson & Johnson's New FDA Approval Lets Lung Cancer Patients Switch To Monthly Dosing Sooner",
      "id": 139135054,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/17/Doctor-Hand-Point-Patient-Lung-X-ray-Fil.jpeg?width=2048&height=1536",
      "related": "JNJ",
      "source": "Benzinga",
      "summary": "FDA approves monthly dosing for J&amp;J&#39;s Rybrevant Faspro with Lazcluze, offering faster, easier treatment for EGFR lung cancer.",
      "url": "https://finnhub.io/api/news?id=cc3da2c18854fedc1a4497c91ee139328afde52de59950129cfba66b5d2ea082"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Income: Lanny's December 2025 Summary",
    "summary": "Dividend Income is the fruit from the labor of investing your money in the stock market. In December, we (my wife and I) received a dividend income total of $8,010.54. Read more here.",
    "url": "https://finnhub.io/api/news?id=f33c489794e022610bcbf402122855e9e87f9bc5d1d052711f2e72440c4d8c39",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771309380,
      "headline": "Dividend Income: Lanny's December 2025 Summary",
      "id": 139121008,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2166399130/image_2166399130.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Dividend Income is the fruit from the labor of investing your money in the stock market. In December, we (my wife and I) received a dividend income total of $8,010.54. Read more here.",
      "url": "https://finnhub.io/api/news?id=f33c489794e022610bcbf402122855e9e87f9bc5d1d052711f2e72440c4d8c39"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: Dominating Immunology While Building Oncology Upside",
    "summary": "The total net revenues of AbbVie's Rinvoq and Skyrizi were about $25.87 billion in 2025, up 46.2% from 2024. Read why ABBV stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=d0d43a6522bc4e441a8332fdd53d2e63617ad866a0c0b56eb5e1f8a2822d2878",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771290687,
      "headline": "AbbVie: Dominating Immunology While Building Oncology Upside",
      "id": 139119790,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1398519163/image_1398519163.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "The total net revenues of AbbVie's Rinvoq and Skyrizi were about $25.87 billion in 2025, up 46.2% from 2024. Read why ABBV stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=d0d43a6522bc4e441a8332fdd53d2e63617ad866a0c0b56eb5e1f8a2822d2878"
    }
  }
]